top of page


Yoga by the Ocean


Patients in our pilot study were some of the first to wear the Phoenix® and experience the relief it can provide.


Find the results from our pilot study below.


caps5 (1).jpg


The FDA requires a 50% responder rate and an average 6 pt reduction in the CAPS-5.

The Phoenix exceeded these requirements and provided an average 18.4 pt reduction in CAPS-5, with only 1 non-responder and 1 non-compliant participant.  These results were statistically and clinically significant with a p-value of .0100 and a 95%CI: 0.57, 0.98.

Quality of Life

The Promis-29 looks at 7 aspects of quality of life and compares responses to the general population to determine severity of responses.


Clinical research


Two-month transcutaneous auricular Vagus Nerve Stimulation (taVNS) take-home device feasibility study in PTSD

Beach Umbrella

White Paper

Post-Traumatic Stress & Transcutaneous Vagal Nerve Stimulation

Clinical Research

  • Assist with protocol development

  • Full training and installation

  • Clinical support

  • IT support for data collection, download and interpretation

  • Repair, maintenance and replacement

Alleviate PTSD symptoms without medications

Evren Launches Phoenix CR for taVNS Researchers

Evren Technologies, an innovator in the field of medical neuromodulation devices, today announced the launch of its pioneering Phoenix CR System, a state-of-the-art transcutaneous auricular vagus nerve stimulator (taVNS) research tool.

 Clinical Trial Contact

Thank you for your interest!

“What do I have to lose?  It’s not a drug that I’m putting in my system and its not something that I’m smoking.  So, if you’re telling me that you can put something in my ear and make me better, sign me up every day of the week!”  


-Pilot Study Participant

bottom of page